SMAC/DIABLO: A Guardian Angel in Boosting Anticancer Drug-Induced Apoptosis

Area of Science:

• Molecular Biology
• Cancer Biology
• Biochemistry

Background:

• Apoptosis is a critical cellular process often dysregulated in cancer, leading to progression and drug resistance.
• SMAC/Diablo (SMAC) is a mitochondrial protein that promotes apoptosis by neutralizing inhibitors of apoptosis (IAPs) and activating caspases.
• While SMAC is often downregulated in cancer, its overexpression in various cancer types suggests complex roles.

Purpose of the Study:

• To review the dual role of SMAC/Diablo in both apoptotic and non-apoptotic cellular functions.
• To explore the significance of SMAC overexpression in cancer cell and tumor growth.
• To discuss the implications of SMAC's non-apoptotic functions in cancer drug resistance.

Main Methods:

• Literature review of studies on SMAC/Diablo function in apoptosis and cancer.
• Analysis of research on SMAC's role in regulating phospholipid synthesis.
• Examination of clinical data and preclinical studies on SMAC mimetics and combination therapies.

Main Results:

• SMAC/Diablo initiates apoptosis by antagonizing IAPs and activating caspases.
• Contrary to its pro-apoptotic function, SMAC is overexpressed in numerous cancers, including lung, breast, and colon.
• Overexpressed SMAC is essential for tumor growth via non-apoptotic regulation of phospholipid synthesis.
• SMAC's role in drug resistance is linked to its non-apoptotic functions.

Conclusions:

• SMAC/Diablo exhibits both pro-apoptotic and non-apoptotic functions, with the latter being critical for cancer progression.
• The overexpression of SMAC in cancer highlights its complex role beyond apoptosis, particularly in phospholipid synthesis.
• Targeting SMAC's non-apoptotic pathways presents a promising strategy for overcoming cancer drug resistance.